Solid Biosciences Inc.

SLDB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016
Operating Activities
Net Income $-52.1M $-21.5M
Depreciation & Amortization
Depreciation $448.0K $56.0K
Amortization
Stock-Based Compensation $5.3M $1.5M
Net Cash from Operating Activities $-43.2M $-20.1M
Investing Activities
Capital Expenditures $2.3M $392.0K
Business Acquisitions
Net Cash from Investing Activities $10.4M $-4.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $77.1M $3.4M
Net Change in Cash $44.3M $-20.8M
Free Cash Flow $-45.5M $-20.5M
← Newer Page 2 of 2 Older →